Literature DB >> 11427462

Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR.

M Komatsu1, D Kobayashi, K Saito, D Furuya, A Yagihashi, H Araake, N Tsuji, S Sakamaki, Y Niitsu, N Watanabe.   

Abstract

BACKGROUND: The significance of serum concentrations of tumor necrosis factor-alpha (TNF-alpha) in the pathogenesis of inflammatory bowel disease (IBD) is uncertain. We measured TNF-alpha in serum from IBD patients by immuno-PCR to analyze the relationship between TNF-alpha and pathophysiologic state in IBD.
METHODS: Serum samples were collected from 54 healthy blood donors, 29 patients with ulcerative colitis (UC; 46 samples), and 7 patients with Crohn disease (CD; 8 samples). DNA label was generated by PCR amplification using biotinylated primer and was bound with streptavidin to biotinylated third antibody. TNF-alpha sandwiched by antibodies was detected by PCR amplification of the DNA label.
RESULTS: TNF-alpha could be measured in all samples. The median serum concentration in IBD patients overall was approximately 390-fold higher than in healthy donors (median increase, 380-fold for UC, 640-fold for CD). The median serum TNF-alpha concentration was 1.7-fold higher in the active stage of UC than in the inactive stage (P <0.05), and this difference could be detected in individual patients.
CONCLUSIONS: Sensitive measurement of serum TNF-alpha could provide an important pathophysiologic marker for the presence and activity of IBD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11427462

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  71 in total

1.  Functionally enhanced siRNA targeting TNFα attenuates DSS-induced colitis and TLR-mediated immunostimulation in mice.

Authors:  Sandra M Ocampo; Carolina Romero; Anna Aviñó; Joan Burgueño; Miguel A Gassull; Jordi Bermúdez; Ramon Eritja; Ester Fernandez; Jose C Perales
Journal:  Mol Ther       Date:  2011-11-01       Impact factor: 11.454

2.  Association of inflammatory cytokine gene polymorphisms with inflammatory bowel disease in a Moroccan cohort.

Authors:  N Senhaji; A Serrano; W Badre; N Serbati; M Karkouri; Y Zaid; S Nadifi; J Martin
Journal:  Genes Immun       Date:  2015-12-03       Impact factor: 2.676

3.  Silence Please!: siRNA approaches to tighten the intestinal barrier in vivo.

Authors:  Kyriaki Bakirtzi; Jill M Hoffman; Charalabos Pothoulakis
Journal:  Am J Pathol       Date:  2013-10-30       Impact factor: 4.307

4.  Tumor suppressor FOXO3 participates in the regulation of intestinal inflammation.

Authors:  Lobke Snoeks; Christopher R Weber; Kaarin Wasland; Jerrold R Turner; Charles Vainder; Wentao Qi; Suzana D Savkovic
Journal:  Lab Invest       Date:  2009-07-27       Impact factor: 5.662

5.  Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease.

Authors:  O Grip; S Janciauskiene; A Bredberg
Journal:  Br J Pharmacol       Date:  2008-09-22       Impact factor: 8.739

6.  Micheliolide, a new sesquiterpene lactone that inhibits intestinal inflammation and colitis-associated cancer.

Authors:  Emilie Viennois; Bo Xiao; Saravanan Ayyadurai; Lixin Wang; Peng G Wang; Quan Zhang; Yue Chen; Didier Merlin
Journal:  Lab Invest       Date:  2014-07-28       Impact factor: 5.662

7.  Association between TNF-alpha and Entamoeba histolytica diarrhea.

Authors:  Kristine M Peterson; Jianfen Shu; Priya Duggal; Rashidul Haque; Dinesh Mondal; William A Petri
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

8.  Intestinal neuroendocrine cells and goblet cells are mediators of IL-17A-amplified epithelial IL-17C production in human inflammatory bowel disease.

Authors:  M Friedrich; J Diegelmann; J Schauber; C J Auernhammer; S Brand
Journal:  Mucosal Immunol       Date:  2014-12-10       Impact factor: 7.313

9.  Grifola frondosa water extract alleviates intestinal inflammation by suppressing TNF-alpha production and its signaling.

Authors:  Jong Suk Lee; Su Young Park; Dinesh Thapa; Mi Kyoung Choi; Ill Min Chung; Young Joon Park; Chul Soon Yong; Han Gon Choi; Jung Ae Kim
Journal:  Exp Mol Med       Date:  2010-02-28       Impact factor: 8.718

10.  Infliximab in ulcerative colitis.

Authors:  Avi Levin; Oren Shibolet
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.